Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1992 Sep;51(9):1089–1093. doi: 10.1136/ard.51.9.1089

Misoprostol in the prevention of gastroduodenal damage in rheumatology.

A B Ballinger 1, P J Kumar 1, D L Scott 1
PMCID: PMC1004847  PMID: 1417145

Abstract

Patients receiving non-steroidal anti-inflammatory drugs (NSAIDs) are at an increased risk of gastroduodenal erosions, ulcers, and the associated complications of haemorrhage, perforation, and death. Many NSAID associated ulcers that bleed or perforate have been asymptomatic until the time of presentation and conversely many patients with dyspepsia do not have ulcers. Symptoms are a poor guide to the presence of an ulcer. During continued treatment with NSAIDs misoprostol is the best choice for NSAID induced gastroduodenal damage; it achieves higher rates of healing than other drugs in these circumstances. Misoprostol is superior to other drugs in the prevention of gastric damage but misoprostol and H2 antagonists are of similar benefit in the duodenum. Prophylactic studies have all used endoscopic damage as an endpoint, and much larger studies will be needed to show an effect of misoprostol on the incidence of ulcer complications. There are no clear guidelines as to which patients should receive prophylactic treatment with misoprostol but those particularly at risk of ulcer complications--that is, those with previous peptic ulceration, the elderly, medically unfit, patients receiving large doses of NSAIDs, and those patients receiving steroids in addition to NSAIDs--should be considered.

Full text

PDF
1089

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agrawal N. M., Roth S., Graham D. Y., White R. H., Germain B., Brown J. A., Stromatt S. C. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med. 1991 Aug 1;115(3):195–200. doi: 10.7326/0003-4819-115-3-195. [DOI] [PubMed] [Google Scholar]
  2. Barrison I. Prophylaxis against non-steroidal induced upper gastrointestinal side effects. Ann Rheum Dis. 1991 Apr;50(4):207–209. doi: 10.1136/ard.50.4.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beardon P. H., Brown S. V., McDevitt D. G. Gastrointestinal events in patients prescribed non-steroidal anti-inflammatory drugs: a controlled study using record linkage in Tayside. Q J Med. 1989 Jun;71(266):497–505. [PubMed] [Google Scholar]
  4. Bjarnason I., Smethurst P., Fenn C. G., Lee C. E., Menzies I. S., Levi A. J. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci. 1989 Mar;34(3):407–411. doi: 10.1007/BF01536263. [DOI] [PubMed] [Google Scholar]
  5. Caldwell J. R., Roth S. H., Wu W. C., Semble E. L., Castell D. O., Heller M. D., Marsh W. H. Sucralfate treatment of nonsteroidal anti-inflammatory drug-induced gastrointestinal symptoms and mucosal damage. Am J Med. 1987 Sep 28;83(3B):74–82. doi: 10.1016/0002-9343(87)90832-1. [DOI] [PubMed] [Google Scholar]
  6. Carson J. L., Strom B. L., Soper K. A., West S. L., Morse M. L. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intern Med. 1987 Jan;147(1):85–88. [PubMed] [Google Scholar]
  7. Chen M. C., Amirian D. A., Toomey M., Sanders M. J., Soll A. H. Prostanoid inhibition of canine parietal cells: mediation by the inhibitory guanosine triphosphate-binding protein of adenylate cyclase. Gastroenterology. 1988 May;94(5 Pt 1):1121–1129. doi: 10.1016/0016-5085(88)90002-9. [DOI] [PubMed] [Google Scholar]
  8. Doube A., Davies J., Notarianni L., Holgate K., Fenn G. C. Effect of misoprostol on concentrations of prostaglandins in synovial fluid. Ann Rheum Dis. 1991 Nov;50(11):797–799. doi: 10.1136/ard.50.11.797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ehsanullah R. S., Page M. C., Tildesley G., Wood J. R. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ. 1988 Oct 22;297(6655):1017–1021. doi: 10.1136/bmj.297.6655.1017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fries J. F., Miller S. R., Spitz P. W., Williams C. A., Hubert H. B., Bloch D. A. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology. 1989 Feb;96(2 Pt 2 Suppl):647–655. doi: 10.1016/s0016-5085(89)80061-7. [DOI] [PubMed] [Google Scholar]
  11. Graham D. Y., Agrawal N. M., Roth S. H. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet. 1988 Dec 3;2(8623):1277–1280. doi: 10.1016/s0140-6736(88)92892-9. [DOI] [PubMed] [Google Scholar]
  12. Graham D. Y., Smith J. L., Spjut H. J., Torres E. Gastric adaptation. Studies in humans during continuous aspirin administration. Gastroenterology. 1988 Aug;95(2):327–333. [PubMed] [Google Scholar]
  13. Griffin M. R., Piper J. M., Daugherty J. R., Snowden M., Ray W. A. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991 Feb 15;114(4):257–263. doi: 10.7326/0003-4819-114-4-257. [DOI] [PubMed] [Google Scholar]
  14. Holvoet J., Terriere L., Van Hee W., Verbist L., Fierens E., Hautekeete M. L. Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a case-control study. Gut. 1991 Jul;32(7):730–734. doi: 10.1136/gut.32.7.730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Isenberg J. I., Smedfors B., Johansson C. Effect of graded doses of intraluminal H+, prostaglandin E2, and inhibition of endogenous prostaglandin synthesis on proximal duodenal bicarbonate secretion in unanesthetized rat. Gastroenterology. 1985 Jan;88(1 Pt 2):303–307. doi: 10.1016/s0016-5085(85)80184-0. [DOI] [PubMed] [Google Scholar]
  16. Kimmey M. B., Silverstein F. E. Role of H2-receptor blockers in the prevention of gastric injury resulting from nonsteroidal anti-inflammatory agents. Am J Med. 1988 Feb 22;84(2A):49–52. doi: 10.1016/0002-9343(88)90254-9. [DOI] [PubMed] [Google Scholar]
  17. Kurata J. H., Abbey D. E. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations. J Clin Gastroenterol. 1990 Jun;12(3):260–266. doi: 10.1097/00004836-199006000-00005. [DOI] [PubMed] [Google Scholar]
  18. Lancaster-Smith M. J., Jaderberg M. E., Jackson D. A. Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers. Gut. 1991 Mar;32(3):252–255. doi: 10.1136/gut.32.3.252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lanza F. L., Aspinall R. L., Swabb E. A., Davis R. E., Rack M. F., Rubin A. Double-blind, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum. Gastroenterology. 1988 Aug;95(2):289–294. doi: 10.1016/0016-5085(88)90482-9. [DOI] [PubMed] [Google Scholar]
  20. Lanza F. L., Graham D. Y., Davis R. E., Rack M. F. Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury. Effect of scoring method. Dig Dis Sci. 1990 Dec;35(12):1494–1499. doi: 10.1007/BF01540567. [DOI] [PubMed] [Google Scholar]
  21. Lanza F. L., Nelson R. S., Rack M. F. A controlled endoscopic study comparing the toxic effects of sulindac, naproxen, aspirin, and placebo on the gastric mucosa of health volunteers. J Clin Pharmacol. 1984 Feb-Mar;24(2-3):89–95. doi: 10.1002/j.1552-4604.1984.tb02770.x. [DOI] [PubMed] [Google Scholar]
  22. Lanza F. L., Royer G. L., Jr, Nelson R. S. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med. 1980 Jul 17;303(3):136–138. doi: 10.1056/NEJM198007173030305. [DOI] [PubMed] [Google Scholar]
  23. Levi S., Goodlad R. A., Lee C. Y., Stamp G., Walport M. J., Wright N. A., Hodgson H. J. Inhibitory effect of non-steroidal anti-inflammatory drugs on mucosal cell proliferation associated with gastric ulcer healing. Lancet. 1990 Oct 6;336(8719):840–843. doi: 10.1016/0140-6736(90)92341-e. [DOI] [PubMed] [Google Scholar]
  24. O'Laughlin J. C., Silvoso G. K., Ivey K. J. Resistance to medical therapy of gastric ulcers in rheumatic disease patients taking aspirin. A double-blind study with cimetidine and follow-up. Dig Dis Sci. 1982 Nov;27(11):976–980. doi: 10.1007/BF01391742. [DOI] [PubMed] [Google Scholar]
  25. Piper J. M., Ray W. A., Daugherty J. R., Griffin M. R. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991 May 1;114(9):735–740. doi: 10.7326/0003-4819-114-9-735. [DOI] [PubMed] [Google Scholar]
  26. Roth S. H., Bennett R. E., Mitchell C. S., Hartman R. J. Cimetidine therapy in nonsteroidal anti-inflammatory drug gastropathy. Double-blind long-term evaluation. Arch Intern Med. 1987 Oct;147(10):1798–1801. [PubMed] [Google Scholar]
  27. Roth S., Agrawal N., Mahowald M., Montoya H., Robbins D., Miller S., Nutting E., Woods E., Crager M., Nissen C. Misoprostol heals gastroduodenal injury in patients with rheumatoid arthritis receiving aspirin. Arch Intern Med. 1989 Apr;149(4):775–779. [PubMed] [Google Scholar]
  28. Shepherd H. A., Fine D., Hillier K., Jewell R., Cox N. Effect of sucralfate and cimetidine on rheumatoid patients with active gastroduodenal lesions who are taking nonsteroidal anti-inflammatory drugs. A pilot study. Am J Med. 1989 Jun 9;86(6A):49–54. doi: 10.1016/0002-9343(89)90157-5. [DOI] [PubMed] [Google Scholar]
  29. Shorrock C. J., Prescott R. J., Rees W. D. The effects of indomethacin on gastroduodenal morphology and mucosal pH gradient in the healthy human stomach. Gastroenterology. 1990 Aug;99(2):334–339. doi: 10.1016/0016-5085(90)91013-v. [DOI] [PubMed] [Google Scholar]
  30. Silvoso G. R., Ivey K. J., Butt J. H., Lockard O. O., Holt S. D., Sisk C., Baskin W. N., Mackercher P. A., Hewett J. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med. 1979 Oct;91(4):517–520. doi: 10.7326/0003-4819-91-4-517. [DOI] [PubMed] [Google Scholar]
  31. Skander M. P., Ryan F. P. Non-steroidal anti-inflammatory drugs and pain free peptic ulceration in the elderly. BMJ. 1988 Oct 1;297(6652):833–834. doi: 10.1136/bmj.297.6652.833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Soll A. H., Weinstein W. M., Kurata J., McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med. 1991 Feb 15;114(4):307–319. doi: 10.7326/0003-4819-114-4-307. [DOI] [PubMed] [Google Scholar]
  33. Somerville K., Faulkner G., Langman M. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet. 1986 Mar 1;1(8479):462–464. doi: 10.1016/s0140-6736(86)92927-2. [DOI] [PubMed] [Google Scholar]
  34. Uribarrena R., Garcíla-Bragado F., Jiménez C., Pérez C., Rivero-Puente A. Laparoscopic findings in two adults with chickenpox. Endoscopy. 1988 Mar;20(2):83–85. doi: 10.1055/s-2007-1018138. [DOI] [PubMed] [Google Scholar]
  35. Van Loenen H. J., Dijkmans B. A., De Vries E. Concentration dependency of cyclosporin and chloroquine as inhibitors of cell proliferation and immunoglobulin production upon mitogen stimulation of mononuclear cells. Clin Exp Rheumatol. 1990 Jan-Feb;8(1):59–61. [PubMed] [Google Scholar]
  36. Van Loenen H. J., Dijkmans B. A., De Vries E. Concentration dependency of cyclosporin and chloroquine as inhibitors of cell proliferation and immunoglobulin production upon mitogen stimulation of mononuclear cells. Clin Exp Rheumatol. 1990 Jan-Feb;8(1):59–61. [PubMed] [Google Scholar]
  37. Walan A., Bader J. P., Classen M., Lamers C. B., Piper D. W., Rutgersson K., Eriksson S. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med. 1989 Jan 12;320(2):69–75. doi: 10.1056/NEJM198901123200201. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES